Developer docs
API playgroundTry for free, no card

Search company profiles

Uro Medical

Full company profile

uuid000c6lx

Namestring
Uro Medical
Legal namestring
Uro Medical Corporation
Websiteurl
uromedical.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Uro Medical Corporation is a privately held, urology-focused medical device company headquartered in Boca Raton, Florida, developing the Protect PNS neurostimulator system for the treatment of overactive bladder (OAB). The company's lead product is a wirelessly powered, battery-free microtechnology implant (0.1 cc in volume, 7 cm long, 1.35 mm in diameter) placed percutaneously at the tibial nerve via a needle, eliminating the need for invasive surgery. Therapy is delivered for approximately 8 hours per day via an external transmitter antenna embedded in clothing, with the Apple iPad serving as the programming device. The platform is designed to address refractory OAB patients who have failed first- and second-line pharmaceutical therapy, competing directly with traditional sacral neuromodulation systems that require implanted batteries replaced every 3-5 years.

Uro Medical is in a pre-commercial phase, currently enrolling patients in two FDA-regulated clinical trials: PROTECT (evaluating urgency urinary incontinence) and GUARDIAN (a ~600-subject randomized study versus standard pharmaceutical management). The company secured CMS coverage for GUARDIAN trial participants in June 2022, establishing a reimbursement pathway for the eventual commercial launch. In July 2021, Uro Medical acquired Micron Medical's urology assets, bringing in the StimGuard SNS System (CE Marked in Europe since May 2018) and adjacent neuromodulation IP. The company holds patented wireless neuromodulation technology and cites clinical outcomes including greater than 80% relief in incontinence episodes.

The intended business model is hardware sales of the Protect PNS implant plus the external transmitter system, distributed through urology and urogynecology clinical practices and hospitals, with reimbursement from Medicare, Medicaid, and private insurers post-FDA approval. No pricing has been publicly disclosed, and the company has no disclosed funding rounds, parent company, or institutional investor backing in the available data. Founded circa 2015 (under predecessor entity StimGuard, with the Uro Medical Corporation branding emerging post the 2021 Micron Medical acquisition), the company operates with 11-50 employees and is pursuing U.S. commercial launch contingent on FDA market authorization.

Short descriptiontext

Uro Medical is a privately held medical device company developing the Protect PNS, a wireless, battery-free microtechnology neurostimulator for treating refractory overactive bladder in patients who have failed pharmaceutical therapy, currently conducting FDA clinical trials ahead of U.S. commercial launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoca Raton, United States
HQ citystring
Boca Raton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
urology medical devices, neuromodulation systems, overactive bladder treatment, tibial nerve stimulation, wireless neurostimulator
Industry1 code
1Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
CodeHLAHAEAKPrimaryYes
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Urology Neuromodulation Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Uro Medical is developing the Protect PNS neurostimulator system for FDA approval to treat overactive bladder. Once approved, the company plans to commercialize the device in the U.S. market with reimbursement coverage from Medicare/Medicaid and private insurers. Revenue will come from device sales and potentially ongoing therapy management services.

aithority.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Protect PNS
Description

Wireless powered, minimally invasive microtechnology neurostimulator system for treatment of overactive bladder (OAB). Currently under FDA regulatory review for market approval.

uromedical.com
Core offering1 text field

Uro Medical develops and manufactures the Protect PNS, a wireless, battery-free microtechnology neurostimulator system designed for the treatment of overactive bladder (OAB). The implant (0.1 cc, 7 cm long, 1.35 mm diameter) is placed at the tibial nerve via needle and powered by an external transmitter embedded in clothing, delivering approximately 8 hours of therapy per day. The company is currently in pre-commercial phase, supporting FDA market authorization through two multi-center clinical trials (PROTECT and GUARDIAN) targeting refractory OAB patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Greater than 80 percent relief in incontinence episodes
+1 more record
Product overview1 text field

Uro Medical is a privately held medical device company engaged in the development, manufacture, and commercialization of wirelessly powered, microtechnology neurostimulators for urology. The company's primary product is the Protect PNS System, an investigational neurostimulation device currently undergoing FDA review for market approval to treat overactive bladder (OAB). The Protect PNS consists of an implanted pulse generator (7 cm long, 1.35 mm diameter) placed at the tibial nerve with an external fabric-embedded transmitter. The company is also conducting two clinical trials (PROTECT and GUARDIAN) to support FDA approval and reimbursement coverage. The company acquired Micron Medical's urology assets including the StimGuard SNS System (CE Mark approved in Europe).

Product and service2 records
1Protect PNS
CategoryUrology neuromodulation device
Description

A wirelessly powered, minimally invasive, microtechnology neurostimulator intended to treat overactive bladder (OAB). The system consists of a 7 cm long, 1.35 mm diameter implanted pulse generator placed at the tibial nerve with an external fabric-embedded transmitter power source; therapy is administered for approximately 8 hours per day. Currently under FDA regulatory review for U.S. market approval; CE Mark approval held by predecessor StimGuard for European availability.

2StimGuard SNS System
CategoryUrology neuromodulation device (acquired/CE Mark product)
Description

World's first wireless programmable neuromodulation device that can be introduced through a needle without surgery for treating overactive bladder. The CE Mark-approved system is 95% smaller than traditional options and uses Apple iPad as its programmer. Acquired by Uro Medical as part of Micron Medical's urology assets and serves as the European-market counterpart to the Protect PNS.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthersAnnounced on2022-06-30
Description

CMS established coverage for participants in the GUARDIAN clinical trial evaluating the Protect PNS neurostimulator device for overactive bladder treatment. This coverage supports the clinical trial and provides a pathway to future reimbursement coverage post-FDA approval.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-07-07
Description

Uro Medical acquired Micron Medical's urology assets including technology and related assets. This acquisition provided Uro Medical with expanded urology-focused neurostimulation technology and assets.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Uro Medical

Urology Neuromodulation Medical Devicesuromedical.com

Uro Medical is a privately held medical device company developing the Protect PNS, a wireless, battery-free microtechnology neurostimulator for treating refractory overactive bladder in patients who have failed pharmaceutical therapy, currently conducting FDA clinical trials ahead of U.S. commercial launch.

What Uro Medical does

Uro Medical Corporation is a privately held, urology-focused medical device company headquartered in Boca Raton, Florida, developing the Protect PNS neurostimulator system for the treatment of overactive bladder (OAB). The company's lead product is a wirelessly powered, battery-free microtechnology implant (0.1 cc in volume, 7 cm long, 1.35 mm in diameter) placed percutaneously at the tibial nerve via a needle, eliminating the need for invasive surgery. Therapy is delivered for approximately 8 hours per day via an external transmitter antenna embedded in clothing, with the Apple iPad serving as the programming device. The platform is designed to address refractory OAB patients who have failed first- and second-line pharmaceutical therapy, competing directly with traditional sacral neuromodulation systems that require implanted batteries replaced every 3-5 years.

Uro Medical is in a pre-commercial phase, currently enrolling patients in two FDA-regulated clinical trials: PROTECT (evaluating urgency urinary incontinence) and GUARDIAN (a ~600-subject randomized study versus standard pharmaceutical management). The company secured CMS coverage for GUARDIAN trial participants in June 2022, establishing a reimbursement pathway for the eventual commercial launch. In July 2021, Uro Medical acquired Micron Medical's urology assets, bringing in the StimGuard SNS System (CE Marked in Europe since May 2018) and adjacent neuromodulation IP. The company holds patented wireless neuromodulation technology and cites clinical outcomes including greater than 80% relief in incontinence episodes.

The intended business model is hardware sales of the Protect PNS implant plus the external transmitter system, distributed through urology and urogynecology clinical practices and hospitals, with reimbursement from Medicare, Medicaid, and private insurers post-FDA approval. No pricing has been publicly disclosed, and the company has no disclosed funding rounds, parent company, or institutional investor backing in the available data. Founded circa 2015 (under predecessor entity StimGuard, with the Uro Medical Corporation branding emerging post the 2021 Micron Medical acquisition), the company operates with 11-50 employees and is pursuing U.S. commercial launch contingent on FDA market authorization.

Uro Medical firmographics

Firmographics
Name
Uro Medical
Legal name
Uro Medical Corporation
Website
https://uromedical.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Uro Medical is a privately held medical device company developing the Protect PNS, a wireless, battery-free microtechnology neurostimulator for treating refractory overactive bladder in patients who have failed pharmaceutical therapy, currently conducting FDA clinical trials ahead of U.S. commercial launch.
Ownership category
akta.pro rank

Uro Medical industry classification

Industry
Product category
Urology Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

  • Urology medical devices
  • Neuromodulation systems
  • Overactive bladder treatment
  • Tibial nerve stimulation
  • Wireless neurostimulator

Where Uro Medical is headquartered

Location

Headquarters

HQ city
Boca Raton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Uro Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Medical Device Sales: Uro Medical is developing the Protect PNS neurostimulator system for FDA approval to treat overactive bladder. Once approved, the company plans to commercialize the device in the U.S. market with reimbursement coverage from Medicare/Medicaid and private insurers. Revenue will come from device sales and potentially ongoing therapy management services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Uro Medical product offering

Product offering

Core offering

Uro Medical develops and manufactures the Protect PNS, a wireless, battery-free microtechnology neurostimulator system designed for the treatment of overactive bladder (OAB). The implant (0.1 cc, 7 cm long, 1.35 mm diameter) is placed at the tibial nerve via needle and powered by an external transmitter embedded in clothing, delivering approximately 8 hours of therapy per day. The company is currently in pre-commercial phase, supporting FDA market authorization through two multi-center clinical trials (PROTECT and GUARDIAN) targeting refractory OAB patients.

Product overview

Uro Medical is a privately held medical device company engaged in the development, manufacture, and commercialization of wirelessly powered, microtechnology neurostimulators for urology. The company's primary product is the Protect PNS System, an investigational neurostimulation device currently undergoing FDA review for market approval to treat overactive bladder (OAB). The Protect PNS consists of an implanted pulse generator (7 cm long, 1.35 mm diameter) placed at the tibial nerve with an external fabric-embedded transmitter. The company is also conducting two clinical trials (PROTECT and GUARDIAN) to support FDA approval and reimbursement coverage. The company acquired Micron Medical's urology assets including the StimGuard SNS System (CE Mark approved in Europe).

Differentiator

Problem solved

Functional benefit

Brands

  • Protect PNS: Wireless powered, minimally invasive microtechnology neurostimulator system for treatment of overactive bladder (OAB). Currently under FDA regulatory review for market approval.

Products and services

  • Protect PNS A wirelessly powered, minimally invasive, microtechnology neurostimulator intended to treat overactive bladder (OAB). The system consists of a 7 cm long, 1.35 mm diameter implanted pulse generator placed at the tibial nerve with an external fabric-embedded transmitter power source; therapy is administered for approximately 8 hours per day. Currently under FDA regulatory review for U.S. market approval; CE Mark approval held by predecessor StimGuard for European availability.
  • StimGuard SNS System World's first wireless programmable neuromodulation device that can be introduced through a needle without surgery for treating overactive bladder. The CE Mark-approved system is 95% smaller than traditional options and uses Apple iPad as its programmer. Acquired by Uro Medical as part of Micron Medical's urology assets and serves as the European-market counterpart to the Protect PNS.

Quantifiable outcome

  • Greater than 80 percent relief in incontinence episodes
  • +1 more outcomes

Companies that use Uro Medical

Customer profile

Segments2 records

Ideal customer profiles2 records

Uro Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Uro Medical partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Center for Medicare and Medicaid Services (CMS)coreOthers · 30 June 2022CMS established coverage for participants in the GUARDIAN clinical trial evaluating the Protect PNS neurostimulator device for overactive bladder treatment. This coverage supports the clinical trial and provides a pathway to future reimbursement coverage post-FDA approval.
  • Micron MedicalcoreTechnology or Integration · 7 July 2021Uro Medical acquired Micron Medical's urology assets including technology and related assets. This acquisition provided Uro Medical with expanded urology-focused neurostimulation technology and assets.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Uro Medical competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights7 records

Customer concentration

Uro Medical social profiles

Digital presence

Uro Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Uro Medical leadership team

Management profile

Number of profiles

Profiles1 record

Uro Medical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Uro Medical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Uro Medical

What does Uro Medical do?

Uro Medical develops and manufactures the Protect PNS, a wireless, battery-free microtechnology neurostimulator system designed for the treatment of overactive bladder (OAB). The implant (0.1 cc, 7 cm long, 1.35 mm diameter) is placed at the tibial nerve via needle and powered by an external transmitter embedded in clothing, delivering approximately 8 hours of therapy per day. The company is currently in pre-commercial phase, supporting FDA market authorization through two multi-center clinical trials (PROTECT and GUARDIAN) targeting refractory OAB patients.

Is Uro Medical a public or private company?

Uro Medical is a private company. It is classified as unknown and is currently operating.

When was Uro Medical founded?

Uro Medical was founded in 2015. It employs 11 to 50 people.

Where is Uro Medical based?

Uro Medical is headquartered in Boca Raton, United States, in the North America region.

How does Uro Medical make money?

One revenue line is on record: medical Device Sales.

Does Uro Medical have an API?

No public API is recorded for Uro Medical.

What industry is Uro Medical in?

Uro Medical's product category is Urology Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireUro Medical Wireless MicroStimulator Secures CMS Coverage of 2nd Clinical Trial for Treatment of Overactive BladderUro Medical Corporation announced that the Center for Medicare and Medicaid Services (CMS) will provide coverage for participants in the GUARDIAN clinical trial, evaluating the Protect PNS neurostimulator device for treatment of overactive bladder. The trial, the second randomized clinical study for the Protect PNS device, is expected to enroll approximately 600 subjects across multiple clinical sites in the United States. Results from the trial will be used to support long-term, nationwide payor reimbursement coverage as a mainline therapy option following FDA market authorization.AiThorityUro Medical Corporation, a privately-held urology-focused medical device company engaged in the development, manufactureUro Medical Corporation announced the acquisition of Micron Medical Corporation’s urology-based assets and initiated the Guardian clinical trial for its Protect PNS device. The company is currently awaiting FDA market approval for Protect PNS to treat refractory overactive bladder, with the new study expected to enroll approximately 600 subjects in the United States.GlobeNewswireUro Medical Corporation Acquires Micron Medical and Initiates the FDA IDE Approved “Guardian” RCT of the Protect PNS Injectable Tibial Stimulator for Treatment of Overactive BladderUro Medical Corporation acquired Micron Medical's urology assets and initiated the Guardian RCT for its Protect PNS injectable tibial stimulator. The trial compares tibial stimulation to medical management for overactive bladder, enrolling about 600 subjects. Results will support payor reimbursement and the company aims for FDA approval.